First in human clinical trial assessing iTOL 102
Latest Information Update: 10 Mar 2025
At a glance
- Drugs ITOL 102 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- 18 Mar 2025 According to an iTolerance, Inc media release, company received US $1.0 million grant from BIRD foundation, the funding will be used to support clinical application of iTOL-102.
- 10 Mar 2025 New trial record
- 25 Feb 2025 According to NLS Pharmaceutics media release, the company announced that Kadimastem and iTolerance successfully completes a pre-IND meeting with the US FDA for iTOL 102 for the treatment of type 1 diabetes mellitus and in preparation of this first in human trial